Assessment of minimal residual disease using droplet digital PCR in cryopreserved ovarian tissue sections from pediatric and adolescent female cancer patients undergoing fertility preservation

Assessment of minimal residual disease using droplet digital PCR in cryopreserved ovarian tissue sections from pediatric and adolescent female cancer patients undergoing fertility preservation - Assessment of minimal residual disease using droplet digital PCR in cryopreserved ovarian tissue sections from pediatric and adolescent female cancer patients undergoing fertility preservation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059034

Enrollment

Registered

2025-10-01

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, malignant lymphoma and other blood disorders, childhood cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with diseases such as leukemia, blood disorders, or malignant tumors. Patients for whom informed consent has been obtained from the patient or guardian.

Exclusion criteria

Exclusion criteria: Cases where consent cannot be obtained. Other cases that the research director or ethics committee deems inappropriate.

Design outcomes

Primary

Measure	Time frame
We will verify whether the results of the PCR (ddPCR: droplet digital PCR) used in this study are consistent with the following: 1. Histopathological test results, 2. Molecular test results, 3. Presence or absence of tumor recurrence after disease treatment, and 4. Life prognosis. Tests 1 and 2 are tests to check for the presence or absence of minimal residual disease (MRD) in ovarian tissue.	—

Secondary

Measure	Time frame
Based on the verification results obtained using ddPCR, ovarian tissue will be transplanted into SCID mice to evaluate whether tumors are formed.	—

Countries

Japan

Contacts

Public ContactDai Keino

Kanagawa Children's Medical Center Division of Hematology/Oncology

d2keino@marianna-u.ac.jp045-711-2351

Outcome results